Clinical practice guidelines for management of disseminated intravascular coagulation in Japan 2024. Part 1: sepsis Clinical practice guidelines for management

• Published in: International journal of hematology Vol. 121; no. 5; pp. 592 - 604
• Main Authors: Yamakawa, Kazuma, Okamoto, Kohji, Seki, Yoshinobu, Ikezoe, Takayuki, Ito, Takashi, Iba, Toshiaki, Gando, Satoshi, Ushio, Noritaka, Totoki, Takaaki, Wada, Takeshi, Asakura, Hidesaku, Ishikura, Hiroyasu, Uchiba, Mitsuhiro, Uchiyama, Toshimasa, Kawasaki, Kaoru, Kawano, Noriaki, Kushimoto, Shigeki, Koga, Shin, Sakamoto, Yuichiro, Tamura, Toshihisa, Nishio, Kenji, Hayakawa, Mineji, Matsumoto, Takeshi, Madoiwa, Seiji, Mayumi, Toshihiko, Yamada, Shinya, Wada, Hideo
• Format: Journal Article
• Language: English
• Published: Singapore Springer Nature Singapore 01.05.2025
• Subjects: Hematology; Medicine; Medicine & Public Health; Oncology; Progress in Hematology; Infection; Sepsis; Thrombomodulin; Antithrombin; DIC
• ISSN: 0925-5710; 1865-3774
• DOI: 10.1007/s12185-024-03896-9

The Japanese Society on Thrombosis and Hemostasis (JSTH) published the first-ever disseminated intravascular coagulation (DIC) guidelines in 2009. Fifteen years later, the JSTH developed new guidelines covering DIC associated with various underlying conditions. These guidelines were developed in accordance with the GRADE system to determine the strength of the recommendations and certainty of the evidence. This article was drafted as Part 1 of an overall DIC guideline covering various underlying conditions, with sepsis as the subject. In this section, seven key clinical issues (questions) are set. Question 1, regarding DIC diagnosis, introduces several diagnostic criteria, such as the JAAM-2, ISTH overt, SIC, and JSTH DIC criteria and recommends choosing the appropriate diagnostic criteria for DIC based on an understanding of their diagnostic properties. For pharmacotherapy in DIC patients with sepsis, we recommend the administration of antithrombin (Question 2) and recombinant thrombomodulin (Question 3) (both GRADE 1B). However, we do not make a clear recommendation regarding the administration of heparin (Question 6) and serine protease inhibitors (Question 7) because of the lack of evidence. Combination therapy, order of administration, and other administration methods for antithrombin and recombinant thrombomodulin are proposed as important future research questions (Questions 4 and 5).